Abbott Laboratories: Strong Medical Devices Performance and Resilient Growth Amid Challenges

TD Cowen analyst Josh Jennings maintained a Buy rating on Abbott Laboratories today and set a price target of $145.00.

Josh Jennings has given his Buy rating due to a combination of factors that highlight Abbott Laboratories’ strengths and potential for growth. Despite a reduction in the 2025 organic sales growth guidance, the areas causing this revision, such as COVID and HIV test sales and China core lab volumes, are not central to the company’s main growth drivers. In contrast, the company’s medical devices segment showed robust performance, with a significant 12% increase in sales, indicating strong demand and growth potential in this area.
Furthermore, Abbott Laboratories exceeded market expectations with its second-quarter revenue and earnings per share, demonstrating its ability to perform well even amid challenges. While there were some misses in the Nutrition and Diagnostics segments, the company outperformed in other areas, such as Established Pharmaceuticals and Medical Devices. These factors, along with a solid gross margin and a slight beat in EPS estimates, contribute to Jennings’s positive outlook and Buy rating for Abbott Laboratories.

In another report released today, Goldman Sachs also reiterated a Buy rating on the stock with a $153.00 price target.